Group One Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.19K Sell
700
-4,700
-87% -$76.8K ﹤0.01% 6435
2026
Q2
$105K Sell
5,400
-28,100
-84% -$509K ﹤0.01% 4811
2026
Q1
$624K Buy
33,500
+3,000
+10% +$49.7K ﹤0.01% 3141
2025
Q4
$402K Sell
30,500
-92,600
-75% -$1.09M ﹤0.01% 3735
2025
Q3
$883K Buy
123,100
+34,800
+39% +$1.81M ﹤0.01% 3161
2025
Q2
$4.17M Buy
88,300
+88,000
+29,333% +$3.58M 0.01% 1467
2025
Q1
$11.7K Sell
300
-65,400
-100% -$2.82M ﹤0.01% 6154
2024
Q4
$3.56M Buy
65,700
+100
+0.2% +$5.11K 0.01% 1420
2024
Q3
$3.31M Sell
65,600
-800
-1% -$37.5K 0.01% 1335
2024
Q2
$2.92M Sell
66,400
-3,500
-5% -$148K 0.01% 1159
2024
Q1
$3.51M Buy
69,900
+47,700
+215% +$2.59M 0.01% 1074
2023
Q4
$1.34M Buy
22,200
+3,500
+19% +$180K ﹤0.01% 2190
2023
Q3
$1.07M Buy
+18,700
New +$1.03M ﹤0.01% 2200

Other funds holding MLTX

Group One Trading's MLTX Position: Q3 2026 in Review

Group One Trading sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2026, closing a stake of 3,179 shares — an estimated $52K sold.

Group One Trading first reported a position in MLTX in Q3 2023 and held it in 7 quarters. The position peaked at $679K in Q1 2024. 169 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Group One Trading reported no remaining MoonLake Immunotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Group One Trading sold 3,179 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $52K.
  • Group One Trading first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 7 quarters.
  • Group One Trading's MoonLake Immunotherapeutics position peaked at $679K in Q1 2024.
  • 169 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.